You Wouldn’t Fix a Car Without Looking Under the Hood—Why Do We Treat Depression and Anxiety That Way?

Most psychiatry for depression and anxiety still centers on prescribing medications—primarily selective serotonin re-uptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) as first-line options. Other categories commonly used for anxiety include benzodiazepines (typically short-term due to dependence risk), buspirone, pregabalin in some guidelines, beta-blockers for performance or situational anxiety, and occasionally tricyclic antidepressants or other agents when first-line options fall short.

These medications can reduce symptoms for many people in the short to medium term. Continuation and maintenance trials show that staying on antidepressants after remission often lowers relapse risk compared with switching to placebo, with relative risks of recurrence frequently around 2.0 in meta-analyses of trials lasting beyond a year. However, the evidence base thins for truly long-term randomized controlled trials extending well past 52 weeks in unselected populations. Many longer studies use enriched designs (patients who already responded acutely), and real-world issues such as tachyphylaxis, withdrawal phenomena on discontinuation, and incomplete remission remain common. Medications primarily modulate neurotransmitter signaling; they do not “cure” underlying patterns of brain dysregulation, nor do they reliably produce durable changes once stopped.

Talk therapy—especially evidence-based approaches such as cognitive behavioral therapy—often produces more enduring effects. Meta-analyses of psychotherapies for depression show moderate benefits that can persist for years after treatment ends. Yet therapy frequently underperforms or plateaus when the brain itself is operating under significant physiological stress: excessive high-beta activity linked to hyperarousal and anxiety, frontal asymmetries associated with mood dysregulation, excess theta or slowing tied to cognitive fog, or impaired autonomic regulation visible in heart-rate variability. In short, psychotropic medications do not restore healthy brain function on their own, and talk therapy works best when the neural substrate can support learning, emotional processing, and self-regulation.

At BrainMax Wellness we refuse to assume the brain is healthy simply because a client meets diagnostic criteria on a symptom checklist. Psychiatry and conventional talk therapy still rely almost exclusively on criteria-referenced assessments (DSM symptom counts, PHQ-9, GAD-7, PCL-5, etc.). These are useful for tracking subjective experience, but they are not biological measures of brain function. You would not treat a suspected fracture without imaging, or adjust insulin without blood glucose data. Why treat complex brain-based conditions without looking at the organ itself?

That is why every new client at Circle C Wellness / Atlanta BrainMax Wellness begins with measurement. We obtain quantitative electroencephalography (qEEG) brain mapping, heart-rate variability, and validated symptom scales before designing care. The guiding principle, stated in my recent paper on Mindful Neurotrauma Cognitive Behavioral Therapy Mitigation, is simple: “We don’t guess, we measure.”

qEEG identifies individualized patterns of dysregulation—elevated high-beta in hyperarousal, frontal asymmetries, theta excess, or connectivity issues—and guides targeted interventions. These include:

• Photobiomodulation (via Vielight devices) to support mitochondrial function, reduce neuroinflammation, and enhance neuroplasticity.

• qEEG-guided neurofeedback (BrainCore systems) that uses real-time operant conditioning to train more adaptive brainwave patterns.

• Trauma-informed mindful cognitive behavioral therapy (TI-MCBT) integrated with advanced reprocessing methods when trauma is present.

• Serial reassessment so protocols adapt to the client’s evolving neurophysiology rather than a fixed recipe.

The full multimodal, measurement-driven protocol for acute trauma is detailed in the open-access paper published in Medical Research Archives (DOI: https://doi.org/10.18103/mra.2026.0384; available at https://esmed.org/MRA/mra/article/view/7701). While that work focuses on the critical early neuroplasticity window after acute trauma, the same philosophy—measure first, personalize, combine bottom-up neuromodulation with top-down psychological work—applies directly to depression, anxiety, and related conditions. Preliminary practice-based observations at our Atlanta clinic show concurrent improvements in self-regulation, sleep, mood, cognitive clarity, and objective qEEG metrics when these elements are combined.

Medications and talk therapy remain valuable tools. They simply work better—and produce more durable results—when we first confirm (or correct) the underlying brain state rather than assuming it is intact. At BrainMax Wellness we do not treat what we have not measured. If you or someone you care about is struggling with depression or anxiety and the standard approaches have plateaued, start by looking at the brain.

Learn more about our measurement-first process at https://www.galencole.com/brainmax and the broader services of Circle C Wellness at https://www.circlecwellness.com. Additional resources and related writing appear on the blog at https://www.galencole.com/blog.

Keywords: measurement-based care, qEEG brain mapping, neurofeedback, BrainCore, photobiomodulation, Vielight, trauma-informed mindful cognitive behavioral therapy, TI-MCBT, BrainMax Wellness, depression treatment, anxiety treatment, precision mental health, Circle C Wellness, Galen Cole, Atlanta brain health, neuroplasticity, acute trauma intervention, Mindful Neurotrauma Cognitive Behavioral Therapy Mitigation.

© 2026 Galen E. Cole. All rights reserved. This original work may be shared with attribution for non-commercial educational purposes.